Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide + Imatinib in CML/Ph+ ALL
NCT00081133Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2003
- Primary completion
- Feb 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose and Rate of Complete Morphologic Remission at 10 weeks. Started Dec 2003; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00081133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081133.